pharma news

News

Regeneron's Libtayo stakes out new territory in skin cancer

Regeneron's Libtayo has become the first checkpoint inhibitor to be cleared by the FDA as an adjuvant treatment for cutaneous squamous cell carcinoma.

News

NICE finalises support for CSL's HAE therapy Andembry

CSL Behring's Andembry can be used to prevent recurrent attacks of HAE by the NHS, following finalised guidance from reimbursement authority NICE.

News

Sanofi, Orano cue up filings for GEP-NET radioligand therapy

Clinical results with GEP-NET radioligand therapy AlphaMedix, a possible rival to Novartis' Lutathera, could lead to regulatory filings.

News

Image of J&J baby powder as originally sold

J&J on the hook for $966m damages in latest talc lawsuit

Johnson & Johnson has suffered a setback in its long-running legal defence against claims its talc products cause cancer.

News

Boehringer bags FDA okay for new pulmonary fibrosis drug

Boehringer's successor to blockbuster IPF therapy Ofev has been approved by the FDA as Jascayd, but will the new drug be a commercial success?

News

After FDA exit, Peter Marks pops up at Lilly

The ousted former director of CBER, Peter Marks, has joined Eli Lilly as head of molecular discovery and infectious disease research.

Regeneron's Libtayo stakes out new territory in skin cancer

NICE finalises support for CSL's HAE therapy Andembry

Sanofi, Orano cue up filings for GEP-NET radioligand therapy

J&J on the hook for $966m damages in latest talc lawsuit

Boehringer bags FDA okay for new pulmonary fibrosis drug

After FDA exit, Peter Marks pops up at Lilly

ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o...

Discover a new era of healthcare panel engagement: Grounded ...

pharma news

Editor's Picks